Caplin Point Laboratories is a Chennai-headquartered pharmaceutical company making injectables, oral solids and other formulations, primarily for Latin America, with a growing US sterile-injectables business. This quarter's print will speak to whether the ~19-20% YoY revenue growth of the last two quarters is sustained, and whether gross margin holds near the company's 'around 60%' commitment amid an open US FDA Form 483 at its Gummidipoondi facility.
| Results date | November 12, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 643.9 Cr (+20.7% YoY) |
| Previous quarter PAT | Rs. 179.1 Cr (+18.8% YoY) |
| Previous quarter EBITDA margin | 38.4% |
| Market cap | Rs. 18,109.79 Cr |
| CMP | Rs. 2,382.5 |
The board meeting is scheduled on November 12, 2026 to approve the unaudited standalone and consolidated financial results for Q2/H1 FY27 (period ended September 30, 2026). The trading window for designated persons was closed from October 1 to November 14, 2026.
A post-results analyst/investor conference call is scheduled on November 12, 2026 at 4:30 PM IST. Chairman C.C. Paarthipan, Vice Chairmen Vivek and Ashok Partheeban, MD Dr. Sridhar Ganesan, and WTD/CFO D. Muralidharan will represent management.
The company paid a total dividend of Rs. 8 per share (400%) for FY26 — a final dividend of Rs. 4 per share plus a ratified interim dividend of Rs. 4 per share. The record date was September 18, 2026, with payment on or before October 24, 2026.
The quarter tests whether the growth acceleration of the last two prints — Q4 FY26 revenue up 19.4% YoY and Q1 FY27 up 19.6% YoY after a 10-11% gestation phase — is sustained, with management's frame of double-digit revenue growth and 25-29% PAT margins for FY27-FY29 entering Q2 intact.
The US engine carries momentum, with Q1 FY27 US revenue of Rs. 137 Cr, up 26% YoY, and the tariff overhang for the US book has eased since the Section 232 notice excluded generic pharmaceutical products, with a 0% generics tariff effective from August 1, 2026 for two years.
On costs, China API/KSM prices were broadly flat sequentially and about 3% lower year on year per Axis Securities, though air freight up 30% YoY and container freight up 10% are offsetting pressures, and the Q1 gross margin of 59.8% (down from 61.7% in Q1 FY26) sits just under management's 'we will stay put around 60%' guide.
The dominant overhang is the US FDA Form 483 with 10 procedural observations at the Gummidipoondi facility from the August 13-21, 2026 inspection — no response submission or inspection classification had been disclosed as of November 7, 2026. The call is also likely to cover delivery against tender markers of $7 million in Central America emergency tenders and $12 million in Chile tenders over 18 months, plus receivables normalization against the guided March/June window.
Guidance scorecard to probe: Management's stated goals and where things stood entering Q2 FY27:
US FDA Form 483 at Gummidipoondi
Growth narrative and balance-sheet markers
Management has guided double-digit revenue growth and 25-29% PAT margins for FY27-FY29, saying margins will be maintained or potentially increase after the stabilization period. Q1 FY27 PAT margin was 27.8%, and management noted 'there might be one or two percentage points up or down, but that 26% to 29% PAT is something where we are comfortable with'.
The Chairman said that if a meaningful acquisition opportunity is found, the company would prefer to put money there, otherwise it would share cash 'in the form of a dividend', adding 'That's not going to dent our cash flow'. The company held free cash reserves of Rs. 1,502 Cr and liquid assets of Rs. 2,875 Cr as of Q1 FY27.
Management attributed the delays to ecosystem challenges in Tamil Nadu, specifically talent availability. It stressed the plant is for backward integration only and does not materially affect current filings, since 100% of current filings use external APIs.
Yes, per the company's own reporting — Q1 FY27 PAT margin of 27.8% sits inside the guided 25-29% band for FY27-FY29, and the long-standing ~25% PAT target has been exceeded with FY26 PAT margin at 28.2%. Management has acknowledged drags from the API unit and Amaris Clinical, which are not yet breaking even.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.